Search the Newsreel

Grifols, S.A. (0RDU.L) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed financial information for Grifols, S.A. (0RDU.L), including its current stock price, historical data, key statistics, performance overview, and financial highlights. It describes Grifols as a company involved in the research, development, production, and marketing of plasma-derived medicines and …

Grifols, S.A. (GRFS) Stock Analysis: Exploring Its 38% Potential Upside in the Healthcare Sector

Grifols, S.A. (GRFS) is highlighted as a compelling investment opportunity in the healthcare sector, with a potential upside of 38.06%. Despite a recent stock dip, the company's strong free cash flow, sustainable dividend, and diverse product offerings position it for growth. Analysts have issued …

Grifols, S.A. Revenue Breakdown – NASDAQ:GRFS

Grifols, S.A. generated 8.88 billion USD in revenue last year, with its Biopharma segment contributing the most at 7.32 billion USD, an increase from the previous year. The United States and Canada were the largest regional contributors, accounting for 4.80 billion USD. The article …

Grifols Reshapes Board and Committee Leadership After Director Resignation

Grifols SA has announced significant changes to its board and committee leadership following the resignation of independent director Iñigo Sánchez-Asiaín Mardones. Joanna Susan Le Couilliard has been appointed as an independent director and chair of the Audit Committee, while Montserrat Muñoz Abellana joins the …

Grifols Half-Year 2026 Results: Profit Jumps as Refinancing Bolsters Balance Sheet

Grifols reported a significant increase in revenue and net profit for the first half of 2026, driven by Biopharma growth and immunoglobulin sales. The company also strengthened its financial position through a major refinancing, extending debt maturities and receiving multiple credit rating upgrades. These …

Grifols, S.A. Pref Class B Revenue Breakdown – MUN:G0F0

Grifols, S.A. Pref Class B (MUN:G0F0) generated 7.52 billion EUR in revenue last year, with its Biopharma segment being the top performer, contributing 6.49 billion EUR. The United States and Canada were the largest regional contributors, accounting for 4.25 billion EUR of the company's …

Grifols (GRFS) reshapes board, Audit and Strategy Committees

Grifols S.A. has announced significant changes to its Board of Directors and key committees. Mr. Iñigo Sánchez-Asiaín Mardones resigned for professional reasons, leading to the appointment of Ms. Joanna Susan Le Couilliard as a new independent director and Chairperson of the Audit Committee. Additionally, …

Grifols (NASDAQ: GRFS) boosts H1 profit 28.7% and refinances 2027 debt

Grifols reported a 28.7% increase in H1 2026 profit to €227 million, with revenue reaching €3.57 billion. The company successfully refinanced all 2027 debt maturities, extending its maturity profile to Q4 2028 and strengthening its financial flexibility. This performance, driven by its Biopharma segment …

Grifols shares jump after Q2 results exceed expectations

Grifols (GRFS) Q2 2026 Earnings Call Transcript

Grifols reported a solid first half of 2026, with group net revenue reaching €3.574 billion, a 2.6% constant currency growth driven primarily by its Biopharma division. The company is on track to meet its full-year 2026 guidance, emphasizing a "smart growth" strategy focused on …

Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test

Grifols has initiated two Phase 3 clinical trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels despite recent stock declines but a 90-day gain. The company's shares are considered 31.6% undervalued with a fair value narrative of €14.40 compared …

Grifols increases revenue by 2.6% to EUR3.6 billion, and net profit by 28.7% to EUR227 million until June

Grifols reported an increase in revenue by 2.6% to EUR3.6 billion and a significant rise in net profit by 28.7% to EUR227 million for the period until June. The company specializes in therapeutic products, medical devices, and plasma-derived products, with primary markets in the …

Grifols, S.A. $GRFS Shares Sold by Whitebox Advisors LLC

Whitebox Advisors LLC reduced its stake in Grifols, S.A. by 21.1% in Q1 2026, selling 553,670 shares but still retaining over 2 million shares. Despite this, other major institutional investors like Royal Bank of Canada and Goldman Sachs increased their positions in the biotechnology …

Flat Footed LLC Buys 287,867 Shares of Grifols, S.A. $GRFS

Flat Footed LLC significantly increased its stake in Grifols, S.A. (NASDAQ:GRFS) during the first quarter, purchasing an additional 287,867 shares to bring its total holding to 1.37 million shares valued at approximately $11.0 million. Other institutional investors like Brandes Investment Partners, Norges Bank, and …

Grifols SA (GRFS) Institutional Confidence

Grifols SA (GRFS) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. Institutional shareholding increased by 2.67% quarter-over-quarter to 57.68%, with Brandes Investment Partners being the largest shareholder despite decreasing their holdings.

Grifols SA (GRFS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Grifols SA (GRFS), identifying its major institutional investors and their holdings. Key shareholders include Brandes Investment Partners, Capital World Investors, and Permian Investment Partners. The report also provides a breakdown of shareholder types and a history of …

GRFS|Grifols SA|Price:7.580|Chg%:+0.040

Grifols SA (GRFS) is a Spain-based global specialty pharmaceutical company with high growth potential, stable fundamentals, and a stock currently considered fairly valued. Despite an average stock market performance recently, the company's revenue and net income have seen significant growth, and institutional ownership remains …

Grifols stock steadies as leverage reduction and earnings trends shape investor focus

Grifols stock performance is currently being shaped by the company's efforts to reduce debt and recent earnings trends. The company, a Barcelona-based plasma specialist, is focusing on deleveraging, improving operating margins, and generating strong cash flow to reassure investors and stabilize its share price. …

Grifols, S.A. Pref Class B Revenue Breakdown – LSX:A2ABZN

Grifols, S.A. Pref Class B (LSX:A2ABZN) generated 7.52 billion EUR in revenue last year. The Biopharma segment was the top-performing segment, contributing 6.49 billion EUR, an increase from 6.14 billion EUR the previous year. The majority of the company's revenue, 4.25 billion EUR, came …

Grifols, S.A. (GRFS) Stock Price, News, Quote & History

This Yahoo Finance article provides a comprehensive overview of Grifols, S.A. (GRFS), a company specializing in plasma-derived medicines and diagnostic equipment. It details the company's stock performance, key financial metrics, business segments, and recent news, alongside analyst insights and comparison with similar pharmaceutical companies.

Grifols stock stabilizes as investors weigh Q1 2024 earnings and leverage metrics

Grifols stock shows stability as investors evaluate its Q1 2024 earnings, marked by improved operating performance but persistently high leverage. The company reported increased revenue and EBITDA, driven by its Bioscience division, and reiterated its commitment to debt reduction and cash generation. While progress …

Earnings Preview: Grifols to Report Financial Results on July 28

Grifols is scheduled to report its financial results on July 28. Investors and analysts will be closely watching the report for insights into the company's performance.

Grifols stock trades steady as debt reduction and margin recovery shape investor focus

Grifols stock is holding steady as the Spanish plasma specialist focuses on debt reduction and margin recovery. Recent quarterly figures show improved adjusted earnings, higher operating margins, and a reduction in net debt, driven by better utilization of plasma centers and cost discipline. The …

Grifols (GRFS) to Post Earnings on Tuesday

Grifols stock trades steady as leverage focus follows debt reduction and 2025 outlook

Grifols stock is holding steady as the company's focus shifts to leverage reduction after successfully lowering debt and providing a positive 2025 outlook. The plasma specialist reported a rebound in operating profitability and a swing to net profit in 2024, driven by increased plasma …

Grifols, S.A. (GRFS) Stock Analysis: Unlocking Potential With A 49.45% Upside

Grifols, S.A. (NASDAQ: GRFS) is presented as an intriguing investment opportunity in the healthcare sector, particularly for its potential upside of 49.45% based on an average target price. Despite a recent revenue decline, the company boasts a strong market position in plasma-derived medicines, an …

Grifols stock steadies on 2025 revenue and debt metrics

Grifols' stock performance is currently being evaluated by investors based on its 2025 financial results, which include €7.64 billion in revenue, €1.63 billion in adjusted EBITDA, and a net debt of €8.8 billion. These figures establish a crucial baseline for assessing the company's profitability, …

GRFS Technical Analysis & Stock Price Forecast

The technical analysis for Grifols SA (GRFS) indicates a "Sell" consensus, driven by various indicators. While some moving averages show "Buy" signals, the MACD, longer-term moving averages, and the overall aggregated signals point towards a bearish outlook. Key support is identified at $7.015 and …

Grifols stock holds focus as 2025 results frame the next move

Grifols stock remains focused on its 2025 financial reporting, with revenue, EBITDA, and cash flow being key metrics guiding investor perception of the Spanish plasma group. The article emphasizes that the company's valuation is driven by its plasma network's scale, collection pace, and conversion …

Grifols stock trades around recent lows as leverage and governance remain under scrutiny

Grifols stock is currently trading near multi-year lows due to persistent investor concerns regarding its high leverage and corporate governance issues. Despite recent quarterly revenue growth and efforts to improve efficiency, the company's significant debt load of over EUR 9 billion and past reporting …

Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com

Grifols has announced the dosing of the first patients in two Phase 3 clinical trials for its immunoglobulin therapeutics, GAMUNEX-C and XEMBIFY. These trials aim to expand the U.S. labels for these treatments, with one focusing on secondary immunodeficiency in blood cancer patients and …

Grifols Trial Could Expand Treatment Options for 60,000 Patients

Grifols has initiated two new Phase 3 trials, SIGMA and XPERT, to expand the U.S. indications for its flagship immunoglobulins, GAMUNEX-C and XEMBIFY. The SIGMA trial focuses on preventing infections in hematologic cancer patients with secondary immunodeficiency, while XPERT aims to demonstrate XEMBIFY's non-inferiority …